如乳腺癌、胰腺癌、肺癌这种重大疾病领域有新靶点、新机制的药品纳入； 在罕见病领域，有螯合剂不耐受的地中海贫血等药品以合理价格纳入目录； 还有一些糖尿病、高胆固醇血症、自身免疫性疾病等慢性病用药方面，也纳入了一些药品，比如一针可 维持半年有效的降脂药物等。 今天（7日），国家医保局公布2025年版国家基本医疗保险、生育保险和工伤保险药品目录和首版商业 健康保险创新药品目录。 今年是国家医保药品目录连续第八年进行调整，从整体上看，这一次药品目录的调整可以从三个角度去 解读，分别是新药品、新伙伴和新机制。 新药品：114个药品新增纳入 多种新药填补治疗空白 这次调整新增纳入114种药品，肿瘤、慢性病等重点领域保障水平进一步提升。其中，有111个为5年内 新上市品种，占比97.3%。 多种新药填补临床治疗上的空白： 这次的创新药高质量发展大会和此前不同的是邀请了很多新伙伴。在会议现场可以看到除了医保部门、 药品生产企业这些熟悉的面孔之外，还包括医药领域的投资人，基金、投资银行的负责人甚至是商业保 险机构的代表也出席了大会。 新伙伴的加入代表了社会对于医保创新的认可，医药既是民生，也是产业。资本市场对于医药创新的持 续 ...

Core Viewpoint - The analysis of five randomized controlled trials from the STEP program indicates that adults treated with semaglutide for obesity are more likely to reduce or stop the use of antihypertensive and lipid-lowering medications compared to those receiving a placebo [4][6][9]. Group 1: Study Findings - Semaglutide, a GLP-1 receptor agonist, is associated with significant weight loss and improvements in various metabolic parameters, leading to a reduction in the need for antihypertensive and lipid-lowering medications [6][12]. - Participants receiving 2.4 mg of semaglutide showed a higher proportion of reduced or stopped antihypertensive or lipid-lowering treatment compared to the placebo group at the end of the treatment [9][10]. - In the analysis, semaglutide-treated participants experienced a greater weight reduction, which correlated with decreased medication needs for hypertension and dyslipidemia [10][12]. Group 2: Specific Data on Antihypertensive and Lipid-Lowering Medications - Among obese adults without diabetes, 17.7% in the semaglutide group stopped antihypertensive medications at 68 weeks, compared to 9% in the placebo group [14]. - In the same group, 16.5% of semaglutide users reduced their antihypertensive treatment intensity, while only 4.8% in the placebo group did so [14]. - For obese adults with type 2 diabetes, 9.8% in the semaglutide group stopped antihypertensive medications, compared to 7.3% in the placebo group [16]. Group 3: Lipid-Lowering Medication Insights - In obese adults without diabetes, 10.1% in the semaglutide group stopped lipid-lowering treatment at 68 weeks, while 4.5% in the placebo group did the same [17]. - The proportion of participants reducing lipid-lowering treatment intensity was similar between groups, with 4% in the semaglutide group and 3.9% in the placebo group [17]. - In the group of obese adults with type 2 diabetes, 10.1% in the semaglutide group stopped lipid-lowering treatment, compared to 5.4% in the placebo group [17]. Group 4: Blood Pressure Relief - Among obese adults without diabetes, 13.7% of those treated with semaglutide achieved hypertension relief at 68 weeks, compared to 6.2% in the placebo group [19]. - In the analysis of obese adults with type 2 diabetes, 5.7% of semaglutide-treated individuals experienced hypertension relief, while 3.4% in the placebo group did [19]. - The findings suggest that significant weight loss can lead to reduced or discontinued use of antihypertensive medications due to improved blood pressure control [19].